Reversing tozasertib resistance in glioma through inhibition of pyruvate dehydrogenase kinases
Esther P. Jane(UPMC Hillman Cancer Center), Ian F. Pollack(University of Pittsburgh)
Cited by 23
Related Papers
Bortezomib Sensitizes Malignant Human Glioma Cells to TRAIL, Mediated by Inhibition of the NF-κB Signaling Pathway
|Molecular Cancer Therapeutics|2011|75
ABT-737 Synergizes with Bortezomib to Induce Apoptosis, Mediated by Bid Cleavage, Bax Activation, and Mitochondrial Dysfunction in an Akt-Dependent Context in Malignant Human Glioma Cell Lines
|Journal of Pharmacology and Experimental Therapeutics|2012|39
Inhibition of Phosphatidylinositol 3-Kinase/AKT Signaling by NVP-BKM120 Promotes ABT-737–Induced Toxicity in a Caspase-Dependent Manner through Mitochondrial Dysfunction and DNA Damage Response in Established and Primary Cultured Glioblastoma Cells
|Journal of Pharmacology and Experimental Therapeutics|2014|35
Survivin Inhibitor YM-155 Sensitizes Tumor Necrosis Factor– Related Apoptosis-Inducing Ligand-Resistant Glioma Cells to Apoptosis through Mcl-1 Downregulation and by Engaging the Mitochondrial Death Pathway
|Journal of Pharmacology and Experimental Therapeutics|2013|28
Abrogation of Mitogen-Activated Protein Kinase and Akt Signaling by Vandetanib Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis in Human Glioma Cells
|Journal of Pharmacology and Experimental Therapeutics|2009|27